Filing Flows › Sunshine Biopharma (SBFM) › Q3 2025
Sunshine Biopharma (SBFM) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
Sunshine Biopharma (SBFM) reported revenue of $9.4M for the third quarter 2025 (Q3 2025), +12% from a year earlier and +0.1% from the quarter before. Operating margin was -11.5%, net loss $884K (9.4% of revenue).
Sunshine Biopharma, Q3 2025: revenue $9.4M (+12% year over year), operating margin -11.5%, net loss $884K, operating cash flow −$747K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.4M | +0.1% | +12% |
| Operating profit | −$1.1M | — | — |
| Net earnings | −$884K | — | — |
| Operating cash flow | −$747K | — | — |
What changed
Revenue was $9.4M in Q3 2025, up 12% year over year and roughly flat from the previous quarter.
Gross margin was 32.6%, down 1.3 points from a year earlier. Operating costs exceeded revenue by $1.1M, an operating margin of -11.5%. Operating expenses grew 5% against revenue growth of 12%. The quarter ended with a net loss of $884K, narrower than the previous quarter's $1.8M loss.
Operating cash flow was −$747K. Non-cash charges added back $96K of depreciation and amortization. Working capital and other items added $41K. Capital expenditures of $8K exceeded it, leaving free cash flow of −$755K.
Questions
What was Sunshine Biopharma's revenue in the third quarter 2025?
Sunshine Biopharma (SBFM) reported revenue of $9.4M for the third quarter 2025 (Q3 2025), +12% from a year earlier and +0.1% from the quarter before.
Was Sunshine Biopharma profitable in the third quarter 2025?
Operating loss was $1.1M (-11.5% of revenue) and net loss $884K.
Source: Sunshine Biopharma 10-Q on SEC EDGAR.